International Immunology Advance Access originally published online on June 23, 2008
International Immunology 2008 20(8):1087-1096; doi:10.1093/intimm/dxn066
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor
1 Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
2 Center for Research on Intracellular Bacteria, Microbiology Institute, CHUV and University of Lausanne, Lausanne, Switzerland
3 Medical Research Council Laboratories, Banjul, The Gambia
4 Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland
5 Swiss Institute for Bioinformatics, Génopode, Lausanne, Switzerland
6 Torrey Pines Institute for Molecular Studies, San Diego, CA, USA
7 Cellular Immunology Laboratory, INSERM U543, Avenir Group, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France
Correspondence to: V. Appay; E-mail: victor.appay{at}chups.jussieu.fr
Melan-A specific CD8+ T cells are thought to play an important role against the development of melanoma. Their in vivo expansion is often observed with advanced disease. In recent years, low levels of Melan-A reactive CD8+ T cells have also been found in HLA-A2 healthy donors, but these cells harbor naive characteristics and are thought to be mostly cross-reactive for the Melan-A antigen. Here, we report on a large population of CD8+ T cells reactive for the Melan-A antigen, identified in one donor with no evidence of melanoma. Interestingly, this population is oligoclonal and displays a clear memory phenotype. However, a detailed study of these cells indicated that they are unlikely to be directly specific for melanoma, so that their in vivo expansion may have been driven by an exogenous antigen. Screening of a Melan-A cross-reactive peptide library suggested that these cells may be specific for an epitope derived from a Mycobacterium protein, which would provide a further example of CD8+ T cell cross-reactivity between a pathogen antigen and a tumor antigen. Finally, we discuss potential perspectives regarding the role of such cells in heterologous immunity, by influencing the balance between protective immunity and pathology, e.g. in the case of melanoma development.
Keywords: cross-reactivity, melanoma, Mycobacterium, T lymphocytes, tumor immunity
Transmitting editor: T. Hünig
Received 4 February 2008, accepted 27 May 2008.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Jandus, G. Bioley, D. Dojcinovic, L. Derre, L. Baitsch, S. Wieckowski, N. Rufer, W. W. Kwok, J.-M. Tiercy, I. F. Luescher, et al. Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts Cancer Res., October 15, 2009; 69(20): 8085 - 8093. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Cole, F. Yuan, P. J. Rizkallah, J. J. Miles, E. Gostick, D. A. Price, G. F. Gao, B. K. Jakobsen, and A. K. Sewell Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor J. Biol. Chem., October 2, 2009; 284(40): 27281 - 27289. [Abstract] [Full Text] [PDF] |
||||

